The dysadherin/carbonic anhydrase 9 axis shapes an acidic tumor microenvironment to promote colorectal cancer progression

Read full text
Authors: Choong-Jae Lee, Hyeon-Ji Yun, Tae-Young Jang, So-El Jeon, Yeong-Hoon Cho, Da-Ye Lim, Eun-Ju Han, Sun-Young Kong, Jeong-Seok Nam
Cited by: 2
References: 57

Abstract

The tumor microenvironment (TME) plays a central role in cancer progression and metastasis. A key feature of the TME is extracellular acidity, which promotes disease progression, immune evasion, and drug resistance. Tumor acidity is increasingly recognized as a critical factor in cancer development and a negative prognostic indicator. Here, we demonstrate that the membrane glycoprotein dysadherin promotes colorectal cancer (CRC) malignancy by modulating TME acidity. Comprehensive bioinformatics and pathological analyses of CRC patient samples revealed that increased tumor acidity is a hallmark of CRC progression and strongly correlates with high expression of dysadherin. Functional studies confirmed that dysadherin enhances malignant traits, particularly under acidic conditions. Mechanistically, dysadherin activates the integrin/FAK/STAT3 signaling pathway, leading to the upregulation of carbonic anhydrase 9 (CA9). CA9 facilitates proton export, contributing to extracellular acidification while maintaining intracellular pH homeostasis, thereby enabling cancer cells to survive and thrive in acidic environments. In a murine liver metastasis model, dysadherin deletion impaired cellular adaptation to the acidic TME and markedly attenuated metastatic colonization, whereas restoring CA9 expression effectively rescued metastatic potential. Overall, our findings identify the dysadherin/CA9 axis as a potential therapeutic target in CRC and provide new insights into how tumors exploit acidosis to drive malignant development and progression.

Fields of Study & Subjects

Cancer Hypoxia and Metabolism Erythrocyte Function and Pathophysiology Phagocytosis and Immune Regulation

Publication details

Journal / source
Signal Transduction and Targeted Therapy
Publisher
Springer Science and Business Media LLC
Volume
11
Issue
1
Pages
19–19
Publication date
15 January 2026
Language
EN